Tokyo, Japan

Fuminao Doi

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 12.8

ph-index = 1


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Fuminao Doi: Innovator in Antibody-Drug Conjugates

Introduction

Fuminao Doi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments for tumors. With a total of 5 patents to his name, Doi continues to push the boundaries of medical science.

Latest Patents

Doi's latest patents include groundbreaking methods for treating tumors through the administration of claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugates. These inventions provide novel antibody-pyrrolodiazepine derivatives and conjugates, which are essential for advancing cancer treatment. Additionally, he has developed antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines, which are useful in creating effective therapies for various medical conditions.

Career Highlights

Fuminao Doi is currently associated with Daiichi Sankyo Company, Limited, where he applies his expertise in drug development. His work has been instrumental in creating innovative solutions that address critical health challenges. Doi's dedication to research and development has positioned him as a key figure in the biotechnology sector.

Collaborations

Doi collaborates with talented professionals in his field, including Narihiro Toda and Yusuke Ota. These partnerships enhance the research and development process, leading to more effective and innovative medical solutions.

Conclusion

Fuminao Doi's contributions to the field of biotechnology and his innovative patents reflect his commitment to improving healthcare. His work continues to inspire advancements in cancer treatment and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…